immunology
-
AbbVie, Sosei Heptares enter $409M deal to discover, develop immunology drugs
The Japanese drugmaker had entered a neurology-focused partnership with Allergan in April 2016. AbbVie acquired Allergan last year, closing the deal in May.
-
MedCity Influencers, BioPharma
Imagining an immune-driven future
The immune system is nature’s most finely-tuned diagnostic, so how will we use it to thwart disease and promote health?
-
Jorie Healthcare CEO Shares Why Automation is Critical to Revenue Cycle Management
The revenue cycle management business is using AI tools to automate cumbersome tasks to help hospitals operate more efficiently. It’s beginning to attract the attention of major healthcare organizations.
-
Glenmark to spin off originator drugs business
The US-based subsidiary will bring together existing research and development and manufacturing businesses in the US, India and Switzerland.
-
BMS, Celgene tout synergies in $74B mega-deal, but Revlimid’s winter is coming
In a call to following news of the deal, executives pointed to near-term launch opportunities and pipelines, but some analysts expressed concern about the loss of patent protection for Revlimid and Opdivo.
-
Pandion raises $58M for its autoimmune platform inspired by the tumor microenvironment
Oncology has long been borrowing lessons from immunology. It may now be time to pay it back. Pandion Therapeutics is tapping into some immune evasion tools observed in cancer to better treat autoimmune and inflammatory disorders.